Companies Dominating the Neuroendocrine Tumor Treatment Market
- BoehringerIngelheim International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Hutchison MediPharma Limited,
- AVEO Oncology
- Pfizer, Inc.
- IpsenPharma
- Tarveda Therapeutics
- Progenics Pharmaceuticals
- Novartis AG
- Eli Lilly & Company
- Ipsen Pharma
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of neuroendocrine tumor treatment is assessed at USD 2.17 billion.
The neuroendocrine tumor treatment market size was over USD 2.04 billion in 2024 and is projected to reach USD 5.62 billion by 2037, witnessing around 8.1% CAGR during the forecast period i.e., between 2025-2037. Increasing incidence of neuroendocrine cancer will boost the market growth.
North America industry is poised to account for largest revenue share of 38% by 2037, backed by high R&D spending by pharmaceutical corporations and regional governments in the region.
The major players in the market include BoehringerIngelheim International GmbH, Hutchison MediPharma Limited, AVEO Oncology, Pfizer, Inc., IpsenPharma, Tarveda Therapeutics, Progenics Pharmaceuticals, Novartis AG, Eli Lilly & Company, Ipsen Pharma
